T. Rowe Price closes Health Sciences Fund to new investors

BOSTON (Reuters) – Investment manager T. Rowe Price Group said on Monday it has closed its Health Sciences Fund to new investors amid a faster pace of inflows, reflecting the sector’s popularity.

Baltimore-based T. Rowe Price said the fund and similar portfolios for institutional clients, focused on healthcare, medicine and life sciences, held $14.8 billion as of April 30. That was up by $5.9 billion since the end of 2013, including $1.8 billion of inflows.

If flows were to continue at the current pace, portfolio manager Taymour Tamaddon said in a statement, “it could eventually strain our ability to invest efficiently and result in a less effective investment strategy.”

Data from Thomson Reuters Lipper unit shows that healthcare and biotech funds, with total assets of $114 billion, had net deposits of $12 billion so far this year through May 27.

That was by far the largest inflow among all sector equity funds. Natural resources funds were in second place with $5.7 billion of inflow in the same period.

The largest fund in the healthcare and biotech sector is the $50 billion Vanguard Health Care Fund, Lipper said.

(Reporting by Ross Kerber; Editing by Dan Grebler)

Subscribe to our newsletter
Never miss another Bankless Times news story as we send you hand-picked articles every morning
We hate spam. Your email address will not be sold or shared with anyone else. You will only receive our daily newsletter. You can unsubscribe at any time.

Leave A Comment

You must be logged in to post a comment.